Nanobiotix News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

26.05.21	NANOBIOTIX to Participate in Fireside Chat at the Jefferies Virtual Healthcare Conference (Businesswire)
25.05.21	Nanobiotix Announces the Appointment of Dr. Gary Phillips as Chairman of the Nanobiotix Supervisory Board (Businesswire)
12.05.21	Nanobiotix to Present at the UBS Global Healthcare Virtual Conference (Businesswire)
11.05.21	NANOBIOTIX Partners With LianBio to Develop and Commercialize Potential First-in-Class Radioenhancer NBTXR3 Across Tumor Types and Therapeutic Combinations in China and Other Asian Markets (Businesswire)
29.04.21	NANOBIOTIX Announces First Quarter Operational and Financial Updates (Businesswire)
12.04.21	Nanobiotix Combined Shareholders Meeting to Be Held April 28, 2021 (Businesswire)
08.04.21	NANOBIOTIX Announces Filing of 2020 Universal Registration Document and 2020 Annual Report on Form 20-F (Businesswire)
17.03.21	NANOBIOTIX Reports Full Year 2020 Financial Results and Highlights Operational Progress (Businesswire)
04.03.21	NANOBIOTIX and PharmaEngine Mutually Agree to Conclude Collaboration (Businesswire)
03.03.21	NANOBIOTIX to Present at the H.C. Wainwright Global Life Sciences Conference (Businesswire)
26.02.21	NANOBIOTIX 2020 Q4 and Annual Revenues (Businesswire)
28.01.21	NANOBIOTIX Announces First Patient Injected With NBTXR3 in Esophageal Cancer (Businesswire)
25.01.21	Nanobiotix Subsidiary Curadigm Secures New Collaboration Agreement With Sanofi Focused on Gene Therapy Pipeline (Businesswire)
15.01.21	Nanobiotix Announces Positive First Results for Novel NBTXR3 in Rectal Cancer Study at ASCO-GI 2021 (Businesswire)
08.01.21	Nanobiotix Announces Key Development Milestones for 2021 After Successful Nasdaq Initial Public Offering (Businesswire)
18.12.20	Nanobiotix Announces Closing of Underwriters’ Option to Purchase Additional ADSs (Businesswire)
15.12.20	NANOBIOTIX Announces Closing of Global Offering and Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Global Offering to $113.3 Million (Businesswire)
11.12.20	NANOBIOTIX Announces Pricing of Global Offering and Approval to List on NASDAQ Global Select Market (Businesswire)
10.12.20	NANOBIOTIX Announces the Filing of an Amended Registration Statement, Including an Estimated Initial Public Offering Range (Businesswire)
07.12.20	Nanobiotix Announces the Start of the Roadshow for Its Proposed Global Offering and Proposed Nasdaq Listing (Businesswire)
07.12.20	NANOBIOTIX Announces the Start of the Roadshow for Its Proposed Global Offering and Proposed Nasdaq Listing (Businesswire)
20.11.20	NANOBIOTIX Files Registration Statement for Proposed Initial Public Offering in the United States (Businesswire)
17.11.20	Nanobiotix Announces Two New Phase II Trials Evaluating NBTXR3 in Combination with Anti-PD-1 for the Treatment of Head and Neck Cancer (Businesswire)
12.11.20	NANOBIOTIX Announces Positive New Pre-clinical Data Suggesting Radioenhancer NBTXR3 Could Have a Significant Impact in Immunotherapy (Businesswire)
10.11.20	NANOBIOTIX Announces Positive First Clinical Data Showing Conversion of Anti-PD-1 Non-Responders to Responders With Radioenhancer NBTXR3 (Businesswire)
26.10.20	NANOBIOTIX Provides Updates on Global Clinical Development Plan for First-in-class Radioenhancer NBTXR3 at ASTRO 2020 (Businesswire)
23.10.20	Nanobiotix Announces Third Quarter 2020 Revenue (Businesswire)
20.10.20	NANOBIOTIX Announces Four Presentations at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting (Businesswire)
13.10.20	NANOBIOTIX Announces First Patient Injected with NBTXR3 in Pancreatic Cancer and Safe to Proceed Notifications for Two Additional Trials From U.S. FDA (Businesswire)
04.09.20	NANOBIOTIX Announces Half-year Financial Statements as at June 30, 2020 (Businesswire)
28.07.20	Nanobiotix Successfully Raises Approximately €20 (us$24) Million in Placement of Ordinary New Shares With Us and European Investors (Businesswire)
27.07.20	Nanobiotix Launches a Capital Increase by Means of an Accelerated Bookbuild Offering (Businesswire)
17.07.20	Nanobiotix Announces Revenue for Second Quarter 2020 and First Half Year 2020 (Businesswire)
17.06.20	Nanobiotix Receives Feedback From US FDA to Advance Phase III Head and Neck Cancer Study Design and CMC Development Plan for NDA (Businesswire)
10.06.20	NANOBIOTIX Spinoff Curadigm Validates Novel Nanoprimer Technology in RNA Therapeutics (Businesswire)
10.06.20	Curadigm Announces Publication of Results Using Proprietary Nanoprimer to Improve RNA Therapeutics in Collaboration With the Langer Lab (Businesswire)
08.06.20	Nanobiotix Secures €10M in Non-Dilutive Financing (Businesswire)
29.05.20	Nanobiotix Announces Positive First Results From Phase I Expansion in Locally Advanced Head and Neck Cancer at ASCO 2020 (Businesswire)
06.05.20	NANOBIOTIX Announces First Phase I Trial With NBTXR3 in Pancreatic Cancer Is Safe to Proceed Per US FDA (Businesswire)
30.04.20	NANOBIOTIX Announces First Quarter 2020 Revenues (Businesswire)
21.04.20	NANOBIOTIX Provides Updates on Clinical Development Continuity in the Context of the COVID-19 Crisis (Businesswire)
17.03.20	NANOBIOTIX 2019 Annual Results (Businesswire)
09.03.20	Curadigm announces the selection of its Nanoprimer technology by the National Cancer Institute for a characterization & development collaboration (Businesswire)
28.02.20	Nanobiotix 2019 Q4 and Annual Revenues (Businesswire)
07.01.20	NANOBIOTIX Announces Plan for Global Phase III Head and Neck Cancer Registration Trial Along With Overall Development Update (Businesswire)
25.10.19	NANOBIOTIX Announces Third Quarter 2019 Revenue (Businesswire)
18.09.19	Phase I Study Results Show First-in-class NBTXR3 Could Present as a Valuable Option for Patients With Hepatocellular Carcinoma or Liver Metastasis (Businesswire)
04.09.19	Nanobiotix Announces Half-year Financial Statements as of June 30, 2019 (Businesswire)
09.07.19	Nanobiotix announces publication of phase III Soft Tissue Sarcoma data for first-in-class NBTXR3 in the Lancet Oncology (GlobeNewswire)
01.07.19	Nanobiotix announces new organizational structure as the company enters its next stage after first european market approval (GlobeNewswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Nanobiotix SA

Aktien Top/Flop

Meistgelesene Nachrichten